

wings4innovation GmbH (w4i) was founded

... as affiliate of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I),
a new European financing vehicle for early-stage drug discovery projects with
focus in Austria and Germany

... to facilitate translation of promising results from Austrian basic research
organisations in life sciences into professional drug discovery projects
and their commercialisation

w4i has access to funds of KHAN-I and
is open to all research organisations in Austria

Main tasks of w4i

- Scouting for innovative project ideas in collaboration with TTOs
- Evaluation of project proposals
- Presentation of elaborated cases to the w4i Advisory Board (AB)
- After AB approval, application for investment by KHAN-I
- Coordination of work packages of funded projects on behalf of KHAN-I
- Drug discovery consulting


Requirements for funding

- Findings & hypotheses that may lead to an **innovative therapy** (small molecules, biologics, ...) in indications with high **unmet medical need**
- Preexisting IP is not a prerequisite
- In-depth scientific know-how at Principal Investigator (PI)
- **Close collaboration** between w4i and PI
- **Active in-kind contribution** by PI
- Technical feasibility, chance for commercialisation
- Approval by the w4i AB and the KHAN-I Investment Advisory Committee

Funding details

- Supplementary and different to existing funding programmes/schemes
- Funding of important translational activities; no funding of basic research or personnel
- Funding of defined work packages as part of a professional drug discovery program, lead and decisions by KHAN-I and w4i
- Specific work packages or experiments may be best performed by the project originator; either by in-kind contribution or by fully paid contract research
- Call for project proposals is open until end of 2023

Concept



Framework Collaboration with 19 Partners Signed




Organisational aspects

- submission of project proposals to info@w4i.org
- guide available at www.w4i.org
- managing director: Peter Nussbaumer
translational guide: Andreas Billich
Wolfgang Sommergruber
- contact: info@w4i.org

Towards successful translation ...

ACADEMIA



INDUSTRY

... by collaboration of strengths

... for creating new, innovative therapies for patients

... sharing risks and sharing rewards (fair share & share fair)

P. Nussbaumer, B. Klebl: *Future Med. Chem.* **2015**, *7*, 1879

Looking forward to many exciting
joint discussions and projects!

www.w4i.org

e-mail: info@w4i.org